Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) declines year over year
Q1 FY2026 weighted avg shares (diluted) of 2.17M shares fell 76.8% year over year, behind the -56.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -51.1% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -76.8% toward the trailing-twelve-month pace of -56.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 966.12K USD
- Year-over-year change
- -89.7%
- 4-year CAGR
- -30.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 966.12K | -89.7% |
| FY2024 | 2024-12-31 | 9.36M | +11.4% |
| FY2023 | 2023-12-31 | 8.4M | +1.7% |
| FY2022 | 2022-12-31 | 8.26M | +102.0% |
| FY2021 | 2021-12-31 | 4.09M | — |
Weighted Avg Shares (Diluted) vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 weighted avg shares (diluted) of 3.96M shares is the lowest of the 2 companies compared; the peer median is 12.42M shares.
- Its year-over-year change of -56.9% is the lowest of 2, against a peer median of +671.4%.
- Over three fiscal years its annual growth of -51.1% compares with a peer median of +331.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 12.42M | +671.4% | +331.9% | |
| LTM Mar 2026 | 3.96M | -56.9% | -51.1% | |
| Peer median (excluding INDP) | 12.42M | +671.4% | +331.9% | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
| Selling, General & Admin | 5.21M | 8.59M | 8.76M | 8.11M | 10.49M |
| Operating Expenses | 7.73M | 14.91M | 16.38M | 15.37M | 19.83M |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| EBITDA | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.73M) | (14.91M) | (16.38M) | (15.37M) | (19.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.72K | 588.11K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17.72K | 588.11K | 955K | 343.72K | (1.02M) |
| Income Before Tax | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| EPS (Diluted) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| Weighted Avg Shares | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
| Weighted Avg Shares (Diluted) | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.